FDA designation for solid tumor treatment. (TY Atid-EDI) I reported previously (28 Jan) that the AGI-134 solid tumor treatment from Israel’s BiolineRX showed promise. The U.S. FDA has just granted Biological Product Designation for the novel immunotherapy compound. Early trials show complete regression of tumors.

https://www.prnewswire.com/news-releases/biolinerx-announces-receipt-of-fda-biological-product-designation-for-novel-cancer-immunotherapy-candidate-agi-134-300753579.html